Bassam Estfan on Twitter: "ALLIANCE A021101 of periop mFOLFIRINOX in BRPC. Hard to explain the difference in resectability with the replacement of one cycle by short radiation! Also question choice of short
Emergence of SBRT in borderline resectable pancreatic cancer: Is it the way forward?
POST SFRO 2022.pptx
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer - The ASCO Post
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer - The ASCO Post
Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer | VJOncology
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas | BMC Cancer
Untitled
Alliance for Clinical Trials in Oncology - Take a look at A021501 – a trial led by @MKatzMD @MDAndersonNews that looks at how well combination chemotherapy and high-dose radiation therapy before surgery
Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer - YouTube
Katz, Nov 4, A021501 summary slides
fig2_schema | The Bulletin
Varian Medical Affairs - Pancreas SBRT 36Gy SIB (Alliance A021501)
Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results | The Bulletin
New Standard for Borderline Resectable Pancreatic Cancer
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era
Frontiers | Clinical Impact of Molecular Subtyping of Pancreatic Cancer
PDF) Alliance for clinical trials in oncology (ALLIANCE) trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Peter Hosein, MD on X: "Long awaited results of the Alliance A021501 for borderline resectable PDAC presented by @mkatzmd @ASCO #GI21. Over to you #Radonctwitter 🧐 https://t.co/rFlVNpSoBW" / X
Neoadjuvant mFOLFIRINOX Established as Reference Standard in Borderline Resectable PDAC
Preoperative combination chemotherapy improved survival in patients with pancreatic cancer | MD Anderson Cancer Center
